IACTA Pharmaceuticals and Pharmaleads to Develop the World s First Epithelial Protective Drug Harnessing Endogenous Analgesia for the Topical Treatment of Acute and Chronic Ocular Pain
News provided by
Share this article
-
License agreement aims to accelerate global development of DENKIs, leveraging expertise and resources of both companies
IRVINE, Calif., PARIS, HONG KONG, Jan. 7, 2021 /PRNewswire/ IACTA Pharmaceuticals, Inc. ( IACTA ) and Pharmaleads, with Pharmaleads Greater China, today announced they have entered into licensing agreements, with IACTA acquiring global rights to Pharmaleads Dual Enkephalinase Inhibitors (DENKI
®), a novel class of non-opioid compounds for the treatment of acute and chronic ocular pain.